ARUP Laboratories
Castleman Disease Educational Portal
Improving the understanding and diagnosis of idiopathic multicentric Castleman disease through pathology education, tools, and collaboration.
Estimated
4,800
New cases recorded each year.
Develops before
30 years
Castleman disease usually develops in most patients before reaching 30.
Our mission is to advance the understanding, diagnosis, and treatment of idiopathic
multicentric Castleman disease (iMCD) by providing healthcare professionals with
cutting-edge tools, educational resources, and research insights.
Subtypes
UCD & iMCD
UCD affects a single lymph node region, while iMCD affects multiple regions.
Approximately
23-45%
Patients with iMCD die within 5 years of diagnosis.
We strive to bridge knowledge gaps and foster collaboration to improve patient care and
outcomes.